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Abstract:  
 
Invasive fungal diseases (IFD) are an important cause of morbidity and mortality in premature 
neonates and immunocompromised paediatric patients. Their diagnostic and therapeutic 
management remains a challenge. A nationwide survey was conducted among thirteen of the 
largest paediatric units in the UK, to obtain insight in the current management of IFD in 
neonates and children. All responding centres were tertiary teaching centres. The use of 
fungal diagnostic tools and imaging modalities varied among centres. Antifungal prophylaxis 
was prescribed in most centres for extreme-low birth weight infants and high risk haemato-
oncological patients, but with a huge variety in antifungals given. An empirical treatment was 
favoured by most centres in case of febrile neutropenia. First line therapy for candidemia 
consists of either fluconazole or liposomal amphotericin B, with voriconazole being first line 
therapy for invasive aspergillosis. Disseminated invasive aspergillosis was most often 
mentioned as a reason to prescribe combination antifungal therapy. In conclusion, this survey 
reinforces the fact that there are still important aspects in the management of paediatric IFD 
which should ideally be addressed in paediatric clinical trials. Attention needs to be given the 
knowledge gaps as observed in the results of our survey to optimize the management of IFD 
in children and neonates. 
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Introduction 
 
There are a number of challenges faced in the management of invasive fungal diseases (IFD) 
in neonates and children: a unique fungal and clinical epidemiology, the unspecific clinical 
presentation, the poorer performance of fungal diagnostic tests, limited pharmacokinetic data 
of the available antifungals with a consequent lack of dosing recommendations, and a lack of 
paediatric randomised control trials. The difficulties in diagnosing IFD, which are characterized 
by a high case-fatality rate, has resulted in an overuse of costly antifungals in high risk patient 
populations (1). Overuse of antifungal agents will favour antifungal resistance development 
and increase unwanted toxicity.   
 
Despite international consensus guidelines about the management of IFD in neonates and  
children, there is still significant variability in the management of IFD and the prescribing 
practices vary across institutions and geographic areas (2–5). In the UK, with the exception of 
the guideline for the management of IFD in paediatric patients undergoing allogeneic 
hematopoietic stem cell transplantation, there is a lack of national consensus guidelines 
addressing the management of IFD in neonates and children. We conducted a nationwide 
survey to be informed about the current clinical management of IFD in the UK.  
 
Methods 
 
A web-based survey was developed in REDCap™ to collect data from participating sites. 
Fifteen centres within the UK were invited to participate in April 2017. Those centres were 
selected due to the volume and complexity of the paediatric services, including the care and 
management for premature neonates and immunocompromised children. The survey was 
addressed to either paediatric infectious diseases clinicians or the paediatric oncologist.  
The main topics addressed in the survey related to hospital characteristics including access 
to diagnostic facilities; use of guidelines; use of diagnostic modalities; antifungal prophylaxis; 
use of TDM; the management of febrile neutropenia in high risk patients; and the management 
of paediatric patients with invasive candidiasis (IC) and aspergillosis (IA).  
The following definitions were used: high risk haemato-oncology patients were defined as 
those with relapsed refractory acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia 
(AML), severe aplastic anaemia, myelodysplastic syndrome or those undergoing allogenic 
haematopoietic stem cell transplant (HSCT). Empiric treatment was defined when antifungals 
were prescribed in patients with prolonged febrile neutropenia or aspecific clinical signs only 
suggestive of IFD (fever driven), while pre-emptive therapy was defined as antifungal 
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treatment started based on a positive microbiological and/or imaging abnormality suggestive 
of IFD (diagnostic driven).  
 
Results 
 
Hospital characteristics 
 
The access to the survey opened in April 2017 and was closed in July 2018. The survey was 
completed by clinicians from 13 teaching hospitals in the UK (response rate 87%): St. 
George ́s Hospital, the Royal Marsden Hospital, Great Ormond Street Hospital, St. Mary ́s 
Hospital and Evelinas Children Hospital in London, the Children ́s Hospital in Oxford, 
Southampton Children ́s Hospital, Bristol Royal Hospital for Children, Alder Hey Children ́s 
Hospital Liverpool, Great North Children ́s Hospital Newcastle, Royal Manchester Children ́s 
Hospital, Leeds Children’s Hospital and Birmingham Children´s Hospital. Nine of those are 
stand-alone paediatric hospitals, three function as integrated paediatric departments within 
the hospital, and one is a designated specialist oncology hospital with a paediatric unit. In 
terms of the services provided, twelve centres have a paediatric intensive care unit (PICU), 
eleven a neonatal intensive care unit (NICU) and ten have a paediatric surgical unit. Twelve 
hospitals care for paediatric haemato-oncology patients with eight having a HSCT unit and 
five providing a solid organ transplant service. Each of the 13 hospitals has a Microbiology 
service on site, with only seven harbouring a dedicated Mycology section. All the centres do 
have access to a Referral Mycology Laboratory if required. All the 13 hospitals have access 
to a Radiology department with CT and MRI imaging services.  
 
Use of guidelines 
 
Of the 13 responding hospitals, 10 (77%) answered to have own local guidelines for the 
management of IFD. Particular attention to neonates and children was given in 8 local 
guidelines, with 2 local guidelines addressing neonates in particular. Nine out of 13 hospitals 
(69%) indicated that they used one of more international guidelines for the management of 
IFD in neonates and children. Six (66%) centres used the IDSA 2016 Practice Guidelines for 
the Diagnosis and Management of Aspergillosis (6) and the IDSA 2016 Practice Guideline for 
the Diagnosis and Management of Candidiasis (7). Five (56%) centres each reported the use 
of the ESCMID Guideline for the Diagnosis and Management of Candida diseases 2012; 
prevention and management of invasive infections in neonates and children caused by 
Candida spp. (8) and the ECIL-4 Guidelines for diagnosis, prevention, and treatment of 
invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-
 
5 
 
cell transplantation (9). Two (22%) centres reported the use of the IDSA 2011 Clinical Practice 
Guideline for the use of antimicrobial agent in neutropenic patients with cancer (10).   
 
Management of fever and neutropenia 
 
Three clinical scenarios were presented to obtain insight in the management strategy of high 
risk patients with neutropenia and persistent fever (> 96 hrs) despite antibacterial therapy. The 
majority of the centres reported to follow an empiric management strategy in the 3 clinical 
scenarios presented (table 1). Although, the 2 management strategies were not mutually 
exclusive as a number of centres responded that both strategies were used. Irrespective of 
the management strategy, all the centres reported liposomal amphotericin B as being the 
antifungal to be prescribed in the clinical scenarios given. One centre, using exclusively a pre-
emptive management strategy, adds voriconazole to the liposomal amphotericin B. Another 
centre reported that this choice of antifungal is made per individual patient with micafungin as 
an alternative to liposomal amphotericin B.  
 
In case of persistent fever in high-risk neutropenic haemato-oncology patients, all centres 
responded that a chest X-ray is part of the standard diagnostic work-up, with 10/13 (77%) also 
including a high resolution CT-chest. Three centres would only perform a high resolution CT-
chest when abnormalities are observed on the chest X-ray. A CT-sinuses is part of the 
standard diagnostic work-up in only 1 centre, the other centres would only perform a CT-
sinuses if clinical symptoms are present. Abdominal ultrasound (US) is performed routinely in 
9 out of the 13 (69%) centres, whereas in the remaining 4 only if clinical symptoms. One centre 
responded that a fundoscopy is performed as part of the standard diagnostic work-up. 
 
Fungal biomarkers  
 
Serum galactomannan testing was reported to be mainly used as a diagnostic tool in both 
high-risk neutropenic patients as well as non-haematology patients (table 2). Only 2 centres 
use serum galactomannan testing as a screening tool. β-D-glucan serum testing is used as a 
diagnostic tool in roughly half of the centres, with only 3 and 1 centres using the test as a 
screening tool in high-risk neutropenic patients and non-haematological patients.  
 
Antifungal Prophylaxis 
 
Antifungal prophylaxis is prescribed by nearly all hospitals (12/13) for high risk haemato-
oncology patients with a huge variation in choice of antifungals. Four centres reported to 
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prescribe different antifungals for prophylactic use. Liposomal amphotericin B (50%), 
itraconazole (42%), posaconazole (25%) and voriconazole (17%) are the most common 
antifungals to be prescribed for prophylaxis. For very low birth weight (VLBW) neonates, 
extreme LBW (ELBW) neonates and premature neonates < 28 weeks of gestation, antifungal 
prophylaxis is prescribed in 55%, 90% and 64% of the hospitals, respectively. Either 
fluconazole (70%) or nystatin (30%) was reported to be the antifungal of choice for those 
neonates. Itraconazole was the antifungal of choice for children with chronic granulomatous 
disease (response from 9 centres), with one centre reporting that or itraconazole or 
voriconazole or posaconazole were used. Of the 5 hospitals performing solid organ 
transplantation in children, 60% reported to prescribe antifungal prophylaxis. Most centres 
(over 65%) responded that antifungal prophylaxis is not prescribed to children admitted to the 
PICU, or children with congenital neutropenia or neonates undergoing surgery. 
   
Management of Candidemia  
 
First line antifungal therapy for candidemia showed a similar pattern in the presented clinical 
scenarios for children being neutropenic, or admitted to the NICU or PICU (table 3). More than 
half of the centres responded to prescribe fluconazole in these patient groups, while the others 
choose to prescribe liposomal amphotericin B. Fluconazole was the preferred first line 
antifungal in non-neutropenic non-critically ill paediatric patients (75%). Eight out of 9 centres 
responded to treat for 2 weeks after the first negative blood culture obtained. In 2 centres the 
CVC is removed as part of the treatment; another 2 will remove the CVC when there are two 
positive blood cultures besides being the patient on adequate antifungal cover; with 9 centres 
indicating that CVC removal will dependent on the clinical condition. Additional investigations 
to exclude dissemination to other organs are performed in all centres responding, with an 
abdominal ultrasound, fundoscopy, echocardiogram and Doppler-ultrasound for signs of 
thrombosis performed in 100%, 92%, 77% and 46%, respectively.  
 
Management of Invasive Pulmonary Aspergillosis 
 
The majority of the centres reported to prescribe voriconazole as first-line therapy for invasive 
pulmonary aspergillosis (table 3). In case of a probable of proven diagnosis of invasive 
pulmonary aspergillosis, 46% (6/13) of the centres perform imaging of the brain (CT or MRI) 
to screen for cerebral dissemination.  
 
Antifungal combination therapy 
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Centres were asked to indicate in which clinical scenarios, antifungal combination therapy 
would be prescribed. Disseminated invasive aspergillosis (10/13) and coverage of a period 
of possible insufficient levels of azole antifungals (6/13) are the most common reasons to 
prescribe antifungal combination treatment. Fungal infections of the central nervous system 
(3/13), initially when results of diagnostic tests are awaited (2/13), Cryptococcal meningitis 
(2/13) and in critically-ill patients (1/13) were less common reasons to prescribe a 
combination of antifungal agents.  
 
Therapeutic Drug Monitoring (TDM) 
 
All the centres have access to perform routine TDM of antifungal agents, but seven centres 
do need to send their samples to another institution. The most common rational to request 
TDM request was routine monitoring of mould-active azoles during treatment (85%). Three 
centres (23%) would perform TDM as well during prophylaxis with mould-active azoles.   
 
 
Discussion  
 
The results of this national survey provides valuable information about the current 
management of IFD neonates and children in the UK. With a response rate of 87%, the results 
represent the clinical practice of 13 large third level university hospitals which captures the 
majority of hospital delivering care for paediatric patients at risk for developing IFD.  
 
Our results, not surprisingly, show a substantial variation in the clinical management of IFD in 
neonates and children. The lack of paediatric specific evidence with respect to diagnostic 
measurement, management strategies, prophylactic and targeted treatment as well the lack 
of dosing recommendations for the newer antifungals, leaves the clinician with lots of 
uncertainties. Nevertheless, the results of our survey also indicate a lack of knowledge on 
certain aspects of the clinical management of IFD in neonates and children. 
 
Looking into the management strategies used, the vast majority of the centres favoured an 
empiric approach. This is most likely influenced by a lack of paediatric studies supporting a 
pre-emptive approach, timely access to fungal diagnostics and a prolonged turn-a-round times 
for specialist fungal tests, as well as the poor outcome when treatment is delayed. A 
diagnostic-driven approach in adult patients has shown to be feasible with more proven 
diagnoses made and a decrease in antifungal use without compromising outcomes (11). At 
the time of the survey, only supportive evidence from a single centre was published for a 
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diagnostic-driven strategy in children (12). Recently though, a randomized controlled study 
has shown that a pre-emptive strategy is as effective as an empirical approach in children with 
cancer and febrile neutropenia, and significantly reducing antifungal use (13). Obviously, 
employing a pre-emptive antifungal strategy is only safe and feasible if access to imaging 
modalities, mycological tests and the performance of a bronchoscopy and bronchoalveolar 
lavage can be delivered in a timely fashion.  
 
Three out of 13 centres are relying on conventional X-ray of the chest to detect signs of IFD. 
As several studies have shown that X-chest is not sensitive enough to detect fungal nodules 
in the earlier phases of pulmonary infection (14,15), this is not a good practice and could 
potentially result in delayed diagnosis. International management guidelines strongly 
recommend to use (high resolution) CT imaging to detect pulmonary IFD (9,16,17).  
 
The value of measuring fungal biomarkers in serum, e.g. galactomannan and β-d-glucan, is 
to exclude invasive fungal disease caused by Aspergillus sp. and Candida sp. Both tests are 
characterized by a high negative predictive value while the positive predictive value is low 
(18,19). Therefore, those tests can have an important place in screening of populations at high 
risk for developing IFD. In our survey, while the majority of the centres (77%) use 
galactomannan testing as a diagnostic test, only 2 centres (15%) use the test as a screening 
tool in high-risk neutropenic patients. Responses were not different with respect to use of 
galactomannan testing in non-haematological patients. Is important though that 
galactomannan is only validated for use in neutropenic patients and its test characteristics in 
non-neutropenic patients is not clear. As samples for galactomannan testing are often sent to 
reference laboratories, prolonging the turn-around-time, this may very well affect its use as a 
screening tool. Half of the centres use the β–d-glucan test as a diagnostic tool with a few using 
it as a screening tool. Guidelines for clinical practice management in the paediatric population 
are discouraging the use of this test (9). Studies have shown that levels in children without 
IFD are higher compared to adults and a paediatric specific cut-off needs to be validated 
(19,20).    
 
Antifungal prophylaxis is used by nearly all centres for high risk haemato-oncology patients 
and ELBW infants. Recommendations in favour of this practice can be found in international 
management guidelines as studies have shown that antifungal prophylaxis is effective in 
lowering the incidence of IFD, although no significant effect has been shown on overall 
outcome (8,9,17). Of note, a huge variation in choice of antifungal for prophylaxis is observed 
in high-risk haemato-oncology patients. This is most likely resulting from comparable quality 
of evidence of studies performed and strength of recommendation given in the various 
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international management guidelines (6,9,17). Half of the centres reported to use liposomal 
amphotericin B for prophylaxis, although dosages are not well studied and it has no label for 
prophylactic use. The main reason to use it for antifungal prophylaxis in the paediatric 
population is the use of vincristine in various chemotherapy protocols excluding the use of 
azole antifungals due to well-known interactions (21,22).   
 
The choice for liposomal amphotericin B as first line empiric therapy is in line with data from 
clinical trials as well as recommendations in the various international guidelines (9,23,24). 
First line treatment in the context of a pre-emptive strategy was reported not to be different. 
As most signs and symptoms suspect for IFD are non-specific with respect to the causative 
fungus, this seems to be a reasonable choice, with adjustments to be made when specific 
microbiological test results are known.   
 
Voriconazole, being the first line treatment for IA, was reported to be the first line treatment in 
far most of the centres. Remarkably, this choice was more or less independent of the age of 
the child, although 2 out of 11 centres would prescribe liposomal amphotericin B instead of 
voriconazole in infants < 2 years of age. It is important to note that dosages have not been 
determined for infants < 2 years of age and it is not licensed for use in this age group 
(8,9,17,25). If a decision is made to use voriconazole in infants < 2 years of age, this should 
be prescribed under strict TDM.  
 
Fluconazole and liposomal amphotericin B were equally reported to be used as first line 
treatment for candidemia in both neonates and children, with the exception of non-neutropenic 
non-critically ill children. This is contrast with the results from an international multicentre 
prospective study in which fluconazole or an echinocandin were mainly used in the treatment 
of paediatric candidemia, with only 15% being treated with liposomal amphotericin B (25). 
Most effective treatment modality for paediatric candidemia is not known and is subject of a 
current international study carried out by the International Pediatric Fungal Network 
(www.ipfn.org). For neonatal candidemia a huge variation in clinical practice has been 
described and studies are lacking to make firm recommendations (26,27). 
 
First line combination antifungal therapy is sporadic prescribed, although disseminated IFD (2 
or more organs) is for most centres (77%) a reason to use combination antifungal therapy. 
The pivotal randomized clinical trial comparing voriconazole versus voriconazole plus 
anidulafungin for primary treatment of IA did not show superiority of the combination therapy 
(28). Although not powered to detect meaningful differences in subsets of included patients, 
higher survival was observed in particular subgroups and might suggest that some patients 
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could benefit of combination antifungal therapy. An international prospective cohort study in 
children with IFD showed no benefit of antifungal combination therapy but an increase in 
adverse events was observed (29).  
In conclusion, this survey reinforces the fact that there are still important aspects in the 
management of paediatric IFD which should ideally be addressed in paediatric clinical trials. 
Attention needs to be given the knowledge gaps as observed in the results of our survey to 
optimize the management of IFD in children and neonates. Access to diagnostic modalities in 
a timely fashion with a short turnaround time of results, are urgently needed to inform clinical 
decision making without unnecessary delay in targeted treatment.  
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Figure 1.  Use of antifungal prophylaxis in the different high risk patient groups in 13 
children’s hospitals in the UK. 
(PICU: Paediatric Intensive Care Unit. CGD: Chronic Granulomatous Disease. CN: 
Congenital Neutropenia. SOT: Solid Organ Transplant. *Neonates and children admitted to 
PICU on broad spectrum antibiotics) 
 
